艺妙神州 develops CAR‑T gene‑cell therapies targeting malignant tumors and has advanced multiple CAR‑T candidates into clinical trials. The company has obtained three clinical trial approvals from the National Medical Products Administration and received Beijing's first gene‑cell drug production license. Management says these regulatory milestones provide a solid foundation for commercialization of its lead CAR‑T product. In the past year the company has completed multiple financings, and this round brings its year‑to‑date total funding to over RMB 500 million. The newest financing is intended to accelerate the commercial launch and scaling of its first CAR‑T therapy, help overcome overseas technology monopolies, and deliver treatments to hundreds of thousands of lymphoma patients annually. The company cites ongoing innovation in key gene‑cell technologies and milestone achievements as drivers of its development and commercialization plans. Immunochina develops CAR-T cell therapies and a lentiviral manufacturing platform, with a lead product IM19 targeting B‑Cell Acute Lymphoblastic Leukemia (B‑ALL) and Non‑Hodgkin’s Lymphoma and a pipeline for multiple solid and liquid tumors. The company presented positive clinical results from a 110‑patient cohort at ASH showing a 93% complete remission rate and a 1‑year relapse‑free survival of 70.5%, data that supported increased investor interest. Immunochina closed a ¥140 million RMB (~$20.4M USD) Series C to expand GMP‑grade manufacturing and continue clinical trials for IM19. It expects to receive two IND approvals within China by year‑end and is accelerating construction of a commercial‑scale GMP manufacturing facility. The company has partnerships with Sartorius and Thermo Fisher Scientific to support manufacturing scale‑up. Immunochina’s founders are Tsinghua University graduates who lead the company’s end‑to‑end cell therapy R&D efforts.

Total raised

$21M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2019